NEW YORK (GenomeWeb) – Cancer Genetics today said that it will collaborate with a researcher at Keck Medicine of the University of Southern California to identify genomic markers of diffuse large B-cell lymphoma.

The Rutherford, NJ-based firm said that it will work with Keck pathologist Imran Siddiqi to identify and evaluate prognostic markers for the disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.